A Randomized, Multicenter, Phase 3 Study Comparing Carfilzomib, Lenalidomide, and Dexamethasone (CRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects With Relapsed Multiple Myeloma
This is a Phase 3, randomized, open-label, multicenter study comparing two treatment
regimens for subjects with relapsed multiple myeloma. Eligible subjects will be randomized
in a 1:1 ratio to receive either the control Rd or CRd. Randomization will be stratified by
β2 microglobulin levels (< vs ≥ 2.5 mg/L), prior bortezomib (no vs yes), and prior
lenalidomide (no vs yes). Subjects will receive the treatment determined by randomization in
28-day cycles until disease progression or unacceptable toxicity (whichever occurs first).
The primary endpoint of this Phase 3 study is progression-free survival.
Interventional
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Progression-free survival (PFS)
The primary objective of this study is to compare PFS in subjects with relapsed multiple myeloma who are receiving CRd vs subjects receiving Rd alone in a randomized multicenter setting.
18 months
No
A. Keith Stewart, MD
Principal Investigator
Division of Hematology/Oncology, Department of Internal Medicine, Mayo Clinic, Scottsdale, Arizona, USA
Austria: Federal Ministry of Health
PX-171-009
NCT01080391
June 2010
March 2014
Name | Location |
---|---|
Mayo Clinic | Rochester, Minnesota 55905 |
Fred Hutchinson Cancer Research Center | Seattle, Washington 98109 |
Indiana University Cancer Center | Indianapolis, Indiana 46202-5265 |
Stanford University | Stanford, California 94305 |
Harrington Cancer Center | Amarillo, Texas 79106 |
Rush University Medical Center | Chicago, Illinois 60612-3824 |
Associates in Oncology and Hematology | Chattanooga, Tennessee 37404 |
Mayo Clinic | Scottsdale, Arizona |
Providence St. Joseph Medical Center | Burbank, California 91505 |
John Theurer Cancer Center at Hackensack University Medical Center | Hackensack, New Jersey 07601 |
The University of Texas, MD Anderson Cancer Center | Houston, Texas 77030 |
Cancer and Blood Disease Center | Lecanto, Florida 34461 |
NYU Clinical Cancer Center | New York, New York 10016 |
UT Southwestern Medical Center at Dallas | Dallas, Texas 75390 |
Weill Cornell Medical College | New York, New York 10021 |
Kansas City Cancer Center, LLC | Overland Park, Kansas 66210 |
Rocky Mountain Blood and Marrow Transplant Program | Denver, Colorado 80218 |
Froedtert & Medical College of Wisconsin | Milwaukee, Wisconsin 53226 |
Redwood Regional Medical Group, Inc | Santa Rosa, California 94503 |
The University of Michigan - Comprehensive Cancer Center | Ann Arbor, Michigan 48109 |
Baylor University Medical Center, Blood & Marrow Transplant Center | Dallas, Texas 75246 |
Scott and White Cancer Research Institute | Temple, Texas 76508 |